Literature DB >> 18729004

Endothelial dysfunction and chronic kidney disease: treatment options.

J Ruth Wu-Wong1.   

Abstract

Endothelial cells detect physical and chemical changes in the blood vessels, and release various factors to counter these changes to maintain homeostasis. Traditional cardiovascular disease risk factors, such as hypertension, dyslipidemia and diabetes, cause endothelial dysfunction characterized by off-balanced vasodilation/vasoconstriction, increased oxidative stress and inflammation, deregulation of thrombosis and fibrinolysis, abnormal smooth muscle cell proliferation, and a deficient repair mechanism. Patients with chronic kidney disease (CKD) have a much higher risk of cardiovascular disease and mortality than the general population. Endothelial dysfunction is commonly observed in CKD, likely preceding other cardiovascular complications. Lipid-lowering agents, such as statins, improve endothelial functions and are effective in reducing cardiovascular disease risk in the general population, but have not demonstrated comparable efficacy in the CKD patient population. Similarly, antidiabetic agents, such as thiazolidinediones, that improve endothelial function in the general population are less efficacious than expected in slowing disease progression and reducing cardiovascular disease risk in CKD patients. Interestingly, agents that activate the vitamin D receptor (VDR) for the treatment of hyperparathyroidism secondary to CKD are associated with a survival benefit in CKD patients that is likely mediated through the effects of the VDR on modulating key components involved in endothelial dysfunction. However, a randomized, clinical study is required to confirm the survival benefit of VDR activation therapy for CKD patients. Results from clinical studies suggest that managing hypertension alone may not be adequate in slowing CKD progression and its related cardiovascular complications. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers that target the renin-angiotensin system slow CKD progression, possibly due to their effects on improving endothelial function, independent of controlling blood pressure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18729004

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  9 in total

1.  The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD.

Authors:  Giovana S Di Marco; Stefan Reuter; Uta Hillebrand; Susanne Amler; Maximilian König; Etienne Larger; Hans Oberleithner; Eva Brand; Hermann Pavenstädt; Marcus Brand
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

2.  CD144+ endothelial microparticles as a marker of endothelial injury in neonatal ABO blood group incompatibility.

Authors:  Hisham A E Awad; Azza A G Tantawy; Rania A El-Farrash; Eman A Ismail; Noha M Youssif
Journal:  Blood Transfus       Date:  2013-11-15       Impact factor: 3.443

3.  Toxicity features of high glucose on endothelial cell cycle and protection by Dan Gua-Fang in ECV-304 in high glucose medium.

Authors:  Xian-Pei Heng; Ke-Ji Chen; Zhen-Feng Hong; Wei-Dong He; Ke-Dan Chu; Jiu-Mao Lin; Hai-Xia Zheng; Liu-Qing Yang; Su-Ping Huang; Yuan-Long Lan; Ling Chen; Fang Guo
Journal:  Chin J Integr Med       Date:  2012-02-09       Impact factor: 1.978

4.  Vitamin d receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats.

Authors:  J Ruth Wu-Wong; William Noonan; Masaki Nakane; Kristin A Brooks; Jason A Segreti; James S Polakowski; Bryan Cox
Journal:  Int J Endocrinol       Date:  2010-02-10       Impact factor: 3.257

5.  Perirenal Fat Promotes Renal Arterial Endothelial Dysfunction in Obese Swine through Tumor Necrosis Factor-α.

Authors:  Shuangtao Ma; Xiang-Yang Zhu; Alfonso Eirin; John R Woollard; Kyra L Jordan; Hui Tang; Amir Lerman; Lilach O Lerman
Journal:  J Urol       Date:  2015-09-28       Impact factor: 7.450

6.  Oxidative stress and its association with cardiovascular disease in chronic renal failure patients.

Authors:  Z Hambali; Z Ahmad; S Arab; H Khazaai
Journal:  Indian J Nephrol       Date:  2011-01

7.  8. Dyslipidemia at Chronic Renal Failure.

Authors:  Victor Blaton
Journal:  EJIFCC       Date:  2009-04-20

8.  Oral and maxillofacial surgery in patients undergoing dialysis for advanced renal disease: report of five cases.

Authors:  Yumi Mochizuki; Hiroyuki Harada; Misaki Yokokawa; Naoya Kinoshita; Kazumasa Kubota; Tomokazu Okado; Haruhisa Fukayama
Journal:  BMC Oral Health       Date:  2018-10-19       Impact factor: 2.757

Review 9.  Prognostic and Diagnostic Value of Endocan in Kidney Diseases.

Authors:  Elisabeth Samouilidou; Virginia Athanasiadou; Eirini Grapsa
Journal:  Int J Nephrol       Date:  2022-03-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.